Evidence map›Paper›PMID 41040520›Full record

ArticleFrontiers in oncology2025

The role of systemic immune inflammation index in predicting melanoma.

Qingxiu Tao, Chunli Wang, Long Zeng, Mengjie Mao, Yingchun Lu, Chunyu Wang, Bin Liu

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qingxiu Tao *School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Chunli Wang *Sichuan Cancer Hospital, Chengdu, Sichuan, China.
Long ZengChengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Mengjie MaoChengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Yingchun LuSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Chunyu WangChengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Bin LiuSichuan Cancer Hospital, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many malignancies arise in the context of chronic infection, persistent irritation, or unresolved inflammation, and the inflammatory environment is closely associated with tumor cell proliferation and metastatic spread. The systemic immune-inflammation index (SII), calculated from peripheral lymphocyte, neutrophil, and platelet counts, has been investigated as a prognostic biomarker in several solid tumors, but its role in melanoma is not well defined. Data from the 2003-2018 cycles of the National Health and Nutrition Examination Survey (NHANES) were analyzed using multivariable logistic regression to assess the association between SII and melanoma. Subgroup analyses were conducted according to sex, age, marital status, body mass index, hypercholesterolemia, and smoking status. A cross-sectional study including 39,200 participants from eight NHANES cycles (2003-2018) was conducted, and logistic regression was applied to quantify the association between SII and melanoma. After categorizing SII into tertiles, the unadjusted model indicated that individuals in the highest tertile had a 57% higher melanoma risk compared with those in the lowest tertile (OR = 1.57; 95% CI, 1.06-2.34; p = 0.024). After adjusting for potential confounders, the highest SII tertile remained associated with a 48% increased risk (OR = 1.48; 95% CI, 1.01-2.01; p = 0.047). Higher SII levels were also significantly associated with increased risk in the hypercholesterolemia subgroup (OR = 1.33; 95% CI, 1.08-1.64; p = 0.008). These findings indicate a moderate positive association between SII and melanoma incidence, suggesting that SII may be a simple and accessible biomarker for early detection. To address the limitations of cross-sectional analysis, an external validation cohort was established at our tertiary oncology center. Between 2017 and 2018, 101 pathologically confirmed melanoma patients and 207 contemporaneous non-melanoma controls were recruited. In multivariable logistic regression, the highest SII tertile was associated with a 2.6-fold higher melanoma risk compared with the lowest tertile (OR = 2.60; 95% CI, 1.19-5.69; p = 0.017). These external data support SII as a potential indicator of melanoma risk; however, further validation in prospective cohort studies is required.

Indexed as

early indicators are studiedinflammationmelanomametastasis and inhibitionsystemic immune-inflammation indextumors

Identifiers

PMID41040520
PMCPMC12483850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.